Abstract
Targeting is one of the major challenges in cancer gene therapy. One approach is to use specific promoters to limit the expression of the transgene to specific cells. It has been demonstrated that rat hexokinase II (HKII) promoter is activated in human tumour cells but not in normal cells. Also human HKII-promoter is known to be active in tumour cells and transcriptionally activated in cells that have mutated p53 gene.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
